OBIO logo

OBIO
Orchestra BioMed Holdings Inc

527
Mkt Cap
$238.33M
Volume
237,410.00
52W High
$5.42
52W Low
$2.20
PE Ratio
-3.53
OBIO Fundamentals
Price
$4.08
Prev Close
$3.98
Open
$3.97
50D MA
$4.24
Beta
1.69
Avg. Volume
158,847.09
EPS (Annual)
-$1.11
P/B
5.66
Rev/Employee
$389,325.58
$133.88
Loading...
Loading...
News
all
press releases
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
More News
News Placeholder
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Orchestra BioMed (OBIO) to Release Quarterly Earnings on Monday
Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-orchestra-biomed-holdings-inc-stock...
MarketBeat·17d ago
News Placeholder
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Growth in Short Interest
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports...
MarketBeat·1mo ago
News Placeholder
Orchestra BioMed (OBIO) to Release Earnings on Wednesday
Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-1-orchestra-biomed-holdings-inc-stock...
MarketBeat·2mo ago
News Placeholder
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold reco...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - HC Wainwright boosted their Q1 2026 earnings per share estimates for Orchestra BioMed in a report released on Monday, March 16th. HC...
MarketBeat·2mo ago
<
1
2
...
>

Latest OBIO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.